Fatty liver disease, now termed MASLD, is increasingly prevalent, particularly among those with weight issues, diabetes, or ...

Fat accumulation in the liver, common in both non-drinkers (NAFLD, now MASLD) and those who consume alcohol (AFLD), may ...

ALT readies Q2 report as investors await fresh updates on pemvidutide program in obesity and liver disease studies.

Sagimet Biosciences (NASDAQ:SGMT) stock rises as Canaccord Genuity endorses the company's liver drug denifanstat as it launches coverage with a Buy. Read more here.

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Background Steatotic liver disease-related hepatocellular carcinoma (SLD-HCC), a rising global challenge, is characterised by ...

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Detailed price information for Madrigal Pharmaceuticals Inc (MDGL-Q) from The Globe and Mail including charting and trades.

Oncoustics Oncoustics initiates FDA study of the OnX Liver Assessment Solution at clinical sites across the US and Canada marking a milesto ...

It's shaping up to be a big year for Boehringer Ingelheim—at least if the FDA plays ball. | Boehringer Chief Medical Officer Lykke Hinsch Gylvin, M.D., set out the German drugmaker's plans to launch ...

Key Points CRISPR Therapeutics is still in its early growth stage.Summit Therapeutics has plenty of upside potential ...